-

Robbins LLP Is Investigating the Officers and Directors of GoHealth, Inc. (GOCO) on Behalf of Shareholders

SAN DIEGO & CHICAGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a class action complaint was filed against GoHealth, Inc. (NASDAQ: GOCO) on behalf of shareholders who acquired GoHealth, Inc. shares pursuant to the Company's July 15, 2020, initial public offering ("IPO"). GoHealth operates a health insurance marketplace.

If you have suffered a loss due to GoHealth's misconduct, click here.

GoHealth (GOCO) Accused of Misleading Shareholders

In September 2019, private equity firm Centerbridge acquired GoHealth for $1.1 billion in equity and cash. According to the complaint, GoHealth reported tremendous growth immediately following the acquisition in preparation for going public, representing that its business model was highly profitable and offered the best lifetime value of commissions per customer acquisition cost of any of its peers.

GoHealth conducted its IPO on July 15, 2020, selling approximately 43.5 million shares for $21.00 per share raising nearly $914 million. However, the complaint alleges that GoHealth's IPO materials were negligently prepared and contained false and misleading statements. Specifically, GoHealth failed to disclose: (i) the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020; (ii) GoHealth suffered from a higher risk of customer churn due to its unique business model; (iii) GoHealth could not retain its customers due to various external and internal factors; (iv) GoHealth had entered into materially less favorable revenue sharing arrangements with its external sales agents; and (v) GoHealth had projected these trends to continue and worsen following the IPO. By September 15, 2020, GoHealth closed at $12.53 per share – a more than 40% decline from its IPO price paid by investors just two months previously.

If you purchased GoHealth, Inc. (GOCO), you have until November 20, 2020, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:

Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against GoHealth settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, incl...
Back to Newsroom